D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock.
A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research note on Tuesday, November 26th.
Check Out Our Latest Report on PSTV
Plus Therapeutics Stock Down 13.1 %
Plus Therapeutics Company Profile
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Read More
- Five stocks we like better than Plus Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- Can TikTok Stock Picks Really Make You Rich?
- Do ETFs Pay Dividends? What You Need to Know
- The “Quality” Rotation: Back to Basics Investing
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.